[{"Name":"Erbb2","In a panel":"No","Disease":"breast cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"HER2\u00a0CISH pharmDxTM Kit","Test manufacturer":"Dako Denmark A\/S","Pmid":"23570400","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"somatic mutation","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":1},{"Name":"Top2A","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Dako TOP2A FISH PharmDx Kit","Test manufacturer":"Dako Denmark A\/S","Pmid":"16234514|22083232|21189395","Treatment":"31703_ 4212_ 454216_ 148673_ 6918223_ 452548_ 36462_ 30323_ 10607","Description":"Top2a is a gene transcribing for topoisomerase protein involved in DNA double stranded break repair_ considered a proliferation marker","Molecular type":"somatic mutation","Clinical trail ID":null,"Molecular ID":"TOP2A","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":2},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"HER2 IQFISH PHARMDX","Test manufacturer":"Dako Denmark A\/S","Pmid":"21685042","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":3},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"INSITE HER-2\/NEU KIT","Test manufacturer":"BIOGENEX LABORATORIES_ INC.","Pmid":null,"Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":4},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"SPOT-LIGHT HER2 CISH KIT","Test manufacturer":"INVITROGEN CORPORATION","Pmid":"19289584|17908324","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":5},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"INFORM HER-2\/NEU","Test manufacturer":"Ventana Medical Systems_ Inc.","Pmid":"21317877|10889820|9179063","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":6},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"DAKO HERCEPTEST","Test manufacturer":"Dako Denmark A\/S","Pmid":"10561248","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":7},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"PATH VYSION HER-2 DNA PROBE KIT","Test manufacturer":"Abbott Molecular Inc.","Pmid":"14750243|16166438|11070153|12047146","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":"NCT01066507","Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":8},{"Name":"Erbb2","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"DakoCytomation Her2 FISH pharmDx\u2122 Kit","Test manufacturer":"Dako Denmark A\/S","Pmid":"21685042","Treatment":"3062316_ 644241_ 5484725_ 208908_ 50067185 (SID)_ 178103510 (SID)","Description":"From FDA A DIRECT FLUORESCENCE IN SITU  HYBRIDIZATION (FISH) ASSAY DESIGNED TO QUANTITATIVELY DETERMINE THE HER2 GENE AMPLIFICATION IN FORMALIN-FIXED_ PARAFFIN-EMBEDDED BREAST CANCER TISSUE SPECIMENS. Her2\/Neu is a gene transcribing for RTK that is found to be overexpressed or mutated in breast cancer","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"ERBB2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":9},{"Name":"PIK3CA","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Therascreen PIK3CA RGQ PCR Kit","Test manufacturer":"QIAGEN GMBH","Pmid":null,"Treatment":"56649450","Description":"a real-time qualitative PCR test for the detection of 11 mutations in PIK3CA gene for eligiblity to treatment","Molecular type":"somatic mutation","Clinical trail ID":"NCT02437318","Molecular ID":"PIK3CA","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":10},{"Name":"KRAS","In a panel":"No","Disease":"colorectal cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Therascreen KRAS RGQ PCR Kit","Test manufacturer":"QIAGEN MANCHESTER LTD","Pmid":"28201998","Treatment":"Erbitux (cetuximab)","Description":"A clinical performance study was conducted to generate data to support the clinical utility of the therascreen KRAS RGQ PCR Kit (referred to as KRAS Kit) as a companion diagnostic test that aids in the identification of patients for treatment with Vectibix (panitumumab). The objective of the study was to assess whether KRAS status as determined by the therascreen KRAS RGQ PCR Kit can be used to select patients with metastatic colorectal cancer (mCRC) who will benefit from Vectibix (panitumumab) treatment.","Molecular type":"somatic mutation","Clinical trail ID":"NCT00339183|NCT00079066","Molecular ID":"KRAS","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":11},{"Name":"KRAS","In a panel":"No","Disease":"colorectal cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Cobas KRAS MUTATION TEST","Test manufacturer":"Roche Molecular Systems_ Inc.","Pmid":"22173329","Treatment":"Erbitux (cetuximab)_ Vectibix (panitumumab)","Description":"The test is intended to be used as an aid in the identification of CRC patients for whom treatment with Erbitux (cetuximab) or with Vectibix (panitumumab) may be indicated based on a no mutation detected result.","Molecular type":"somatic mutation","Clinical trail ID":null,"Molecular ID":"KRAS","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":12},{"Name":"ALK","In a panel":"No","Disease":"lung non-small cell carcinoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_3908","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"VYSIS ALK Break Apart FISH Probe Kit","Test manufacturer":"ABBOTT MOLECULAR INC","Pmid":"28838404","Treatment":"Xalkori (crizotinib)","Description":"The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed_ paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens to aid in identifying patients eligible for treatment with Xalkorie (crizotinib).","Molecular type":"somatic mutation","Clinical trail ID":"NCT00585195|NCT00932451|NCT00932893","Molecular ID":"ALK","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":13},{"Name":"EGFR","In a panel":"No","Disease":"lung non-small cell carcinoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_3908","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Cobas EGFR MUTATION TEST v2","Test manufacturer":"Roche Molecular Systems_ Inc.","Pmid":"28838392","Treatment":"Tarceva (erlotinib)","Description":"The cobas EGFR Mutation Test is a real-time PCR test for the qualitative detection of exon 19 deletions and exon 21 (L858R) substitution mutations of the epidermal growth factor receptor (EGFR) gene in DNA derived from formalin-fixed paraffin-embedded (FFPET) human non-small cell lung cancer (NSCLC) tumor tissue","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"EGFR","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":14},{"Name":"EGFR","In a panel":"No","Disease":"lung non-small cell carcinoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_3908","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"QIAGEN MANCHESTER LTD","Test manufacturer":"THERASCREEN EGFR RGQ PCR KIT","Pmid":"27737606|26891729","Treatment":"GILOTRIFTM (afatinib)","Description":"The therascreen EGFR RGQ PCR Kit is a real-time PCR test for the qualitative detection of exon 19 deletions and exon 21 (L858R) substitution mutations of the epidermal growth factor receptor (EGFR) gene in DNA derived from formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tumor tissue.","Molecular type":"amplification","Clinical trail ID":"NCT00949650","Molecular ID":"EGFR","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":15},{"Name":"EGFR","In a panel":"No","Disease":"lung non-small cell carcinoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_3908","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Cobas EGFR MUTATION TEST v2","Test manufacturer":"Roche Molecular Systems_ Inc.","Pmid":"28838392","Treatment":"TARCEVA (erlotinib)","Description":"The cobas EGFR Mutation Test v2 was originally approved as a prior version for the qualitative detection of defined mutations in the epidermal growth factor receptor (EGFR) gene in DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anti- coagulated peripheral whole blood and associated therapeutic indications.","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"EGFR","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":16},{"Name":"EGFR","In a panel":"No","Disease":"lung non-small cell carcinoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_3908","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Cobas EGFR MUTATION TEST v2","Test manufacturer":"Roche Molecular Systems_ Inc.","Pmid":"28838392","Treatment":"TARCEVA (erlotinib)_ TAGRISSOTM (osimertinib)","Description":"The cobas EGFR Mutation Test v2 (P120019\/S007) was approved on November 13_ 2015 for the qualitative detection of defined mutations in the epidermal growth factor receptor (EGFR) gene in DNA derived from formalin-fixed paraffin-embedded tumor tissue (FFPET) from non-small cell lung cancer (NSCLC) patients.","Molecular type":"amplification","Clinical trail ID":null,"Molecular ID":"EGFR","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":17},{"Name":"PCA3","In a panel":"No","Disease":"prostate cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_10283","Usage":"RiskBM","Evidence level":"clinical use","Source":"Urine","Assay\/Test":"PROGENSA PCA3 Assay","Test manufacturer":"Gen-Probe_ Inc.","Pmid":"21405964","Treatment":"PROGENSA PCA3 Assay","Description":"The PROGENSA PCA3 Assay is an in vitro nucleic acid amplification test. The assay measures the concentration of prostate cancer gene 3 (PCA3) and prostate-specific antigen (PSA) RNA molecules and calculates the ratio ofPCA3 RNA molecules to PSA RNA molecules (PCA3 Score) in post-digital rectal exam (DRE) first catch male urine specimens.","Molecular type":"amplification","Clinical trail ID":"NCT01024959","Molecular ID":"PCA3","Type":"Molecular Biomarker","Source ID":"UBERON_0001088","Id":18},{"Name":"BRAF","In a panel":"No","Disease":"melanoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1909","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Roche cobas DNA Sample Preparation Kit|COBAS 4800 BRAF V600 MUTATION TEST","Test manufacturer":"Roche Molecular Systems_ Inc. (RMS)","Pmid":"22391147","Treatment":"Vemurafenib","Description":"The cobas 4800 BRAF V600 Mutation Test is a real-time PCR test on the cobas 4800 system_ and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with vemurafenib.","Molecular type":"somatic mutation","Clinical trail ID":"NCT01107418","Molecular ID":"BRAF","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":19},{"Name":"BRAF","In a panel":"No","Disease":"melanoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1909","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"THXID-BRAF KIT","Test manufacturer":"BioMerieux_ Inc.","Pmid":"25037456","Treatment":"Dabrafenib [Tafinlar] and Trametinib [MekinistTM]","Description":"The THxIDTM BRAF kit is a real-time PCR test on the ABI 7500 Fast Dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with dabrafenib [Tafinlar\u00ae] and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib [MekinistTM].","Molecular type":"somatic mutation","Clinical trail ID":"NCT01153763","Molecular ID":"BRAF","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":20},{"Name":"Scgb2a1,Krt19","In a panel":"No","Disease":"breast Cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"DiagnosticBM|PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"GeneSearch Breast Lymph Node (BLN) Test Kit","Test manufacturer":"Veridex_ LLC.","Pmid":"20557308|23322090","Treatment":null,"Description":"From EDRN SCGB2A1 encodes a small secreted protein from the secretoglobin family_ part of the uterglobin superfamily.  SCGB2A1 is normally expressed in the thymus_ trachea_","Molecular type":"amplification","Clinical trail ID":"NCT00869674","Molecular ID":"SCGB2A1|KRT19","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":21},{"Name":"BRCA1,BRCA2","In a panel":"No","Disease":"breast cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"RiskBM","Evidence level":"experimental","Source":"Saliva","Assay\/Test":"23andMe PGS Genetic Health Risk Report for BRCA1\/BRCA2 (Selected Variants)","Test manufacturer":"23andMe","Pmid":"24520936|9145676","Treatment":"Olaparib","Description":"From FDA The report describes if a woman is at increased risk of developing breast and ovarian cancer_ and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. From EDRN BRCA1 is a nuclear phosphoprotein that functions as a tumor suppressor...[and] thus plays a role in transcription_ DNA repair of double-stranded breaks_ and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers.","Molecular type":"somatic mutation","Clinical trail ID":"NCT01598597","Molecular ID":"BRCA1|BRCA2","Type":"Molecular Biomarker","Source ID":"UBERON_0001836","Id":22},{"Name":"ACTR3B,ANLN,BAG1,BCL2,BIRC5,BLVRA,CCNE1,CDC20,CDC6,CDH3,CENPF,CEP55,CXXC5,EGFR,ERBB2,ESR1,EXO1,FGFR4,FOXA1,FOXC1,GPR160,GRB7,KIF2C,KRT14,KRT17,KRT5,MAPT,MDM2,MELK,MIA,MKI67,MLPH,MYBL2,MYC,NAT1,PGR,PHGDH,PTTG1,RRM2,SFRP1,SLC39A6,TYMS,UBE2C,UBE2T","In a panel":"No","Disease":"breast cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Prosigna Breast Cancer Prognostic Gene Signature Assay","Test manufacturer":"Nanostring Technologies","Pmid":"24625003|26297356","Treatment":null,"Description":"The qualitative assay utilizes gene expression data_ weighted together with clinical variables to generate a risk category and numerical score_ to assess a patient\u2019s risk of distant recurrence of disease","Molecular type":"multigene prediction","Clinical trail ID":"NCT01899079","Molecular ID":"ACTR3B|ANLN|BAG1|BCL2|BIRC5|BLVRA|CCNE1|CDC20|CDC6|CDH3|CENPF|CEP55|CXXC5|EGFR|ERBB2|ESR1|EXO1|FGFR4|FOXA1|FOXC1|GPR160|GRB7|KIF2C|KRT14|KRT17|KRT5|MAPT|MDM2|MELK|MIA|MKI67|MLPH|MYBL2|MYC|NAT1|PGR|PHGDH|PTTG1|RRM2|SFRP1|SLC39A6|TYMS|UBE2C|UBE2T","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":23},{"Name":"NDRG4,BMP3,KRAS,ACTB","In a panel":"No","Disease":"colorectal cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Usage":"DiagnosticBM|PrognosticBM","Evidence level":"clinical use","Source":"Feces","Assay\/Test":"Cologuard","Test manufacturer":"Exact Sciences Corporation","Pmid":"25514307","Treatment":null,"Description":"Cologuard is an in vitro diagnostic device designed to analyze patients stool for the presence of colorectal cancer (CRC) and pre-malignant colorectal neoplasia (Advanced Adenoma or AA) through detection of hemoglobin_ multiple DNA methylation and mutational markers_ and the total amount of human DNA. Specifically_ Cologuard is designed to detect three (3) independent categories of biomarkers that exhibit an additive association with CRC and AA.","Molecular type":"multigene prediction","Clinical trail ID":"NCT01260168","Molecular ID":"NDRG4|BMP3|KRAS|ACTB","Type":"Molecular Biomarker","Source ID":"UBERON_0001988","Id":24},{"Name":"BRCA1,BRCA2","In a panel":"No","Disease":"ovarian cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_2394","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Blood","Assay\/Test":"BRACAnalysis CDx","Test manufacturer":"Myriad Genetic Laboratories_ Inc.","Pmid":"26292709","Treatment":"LynparzaTM (olaparib)","Description":"BRACAnalysis CDxTM is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron\/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.","Molecular type":"somatic mutation","Clinical trail ID":"NCT00753545|NCT01078662","Molecular ID":"BRCA1|BRCA2","Type":"Molecular Biomarker","Source ID":"UBERON_0000178","Id":25},{"Name":"BBC3,EGLN1,TGFB3,ESM1,IGFBP5,FGF18,SCUBE2,FLT1,HRASLS,STK32B,RASSF7,DCK,MELK,EXT1,GNAZ,EBF4,MTDH,PITRM1,CCNE2,ECT2,CENPA,LIN9,NUSAP1,TSPYL5,RUNDC1,PRC1,RFC4,RECQL5,CDCA7,DTL,COL4A2,GPR180,MMP9,RTN4RL1,DIAPH3,CDC42BPA,ALDH4A1,OXCT1,GMPS,GSTM3,SLC2A3,EGLN1,SERF1A,NMU,UCHL5,AP2B1,MS4A7,RAB6B","In a panel":"No","Disease":"breast cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_1612","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"MammaPrint","Test manufacturer":"Agendia BV","Pmid":"27557300|23371464","Treatment":null,"Description":"genes involved in the six hallmarks of cancer (i.e. evasion of apoptosis_ limitless replication_ dysregulation of growth signals_ etc.)_ https\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2999994\/","Molecular type":"multigene prediction","Clinical trail ID":"NCT00433589","Molecular ID":"BBC3|EGLN1|TGFB3|ESM1|IGFBP5|FGF18|SCUBE2|FLT1|HRASLS|STK32B|RASSF7|DCK|MELK|EXT1|GNAZ|EBF4|MTDH|PITRM1|CCNE2|ECT2|CENPA|LIN9|NUSAP1|TSPYL5|RUNDC1|PRC1|RFC4|RECQL5|CDCA7|DTL|COL4A2|GPR180|MMP9|RTN4RL1|DIAPH3|CDC42BPA|ALDH4A1|OXCT1|GMPS|GSTM3|SLC2A3|EGLN1|SERF1A|NMU|UCHL5|AP2B1|MS4A7|RAB6B","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":26},{"Name":"BRCA1,BRCA2","In a panel":"No","Disease":"ovarian cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_2394","Usage":"PrognosticBM|PredictiveBM","Evidence level":"experimental","Source":"Tissue","Assay\/Test":"FoundationFocus CDxBRCA","Test manufacturer":"FOUNDATION MEDICINE_ INC","Pmid":"29977351","Treatment":"RubracaTM (rucaparib)","Description":"The FoundationFocusTM CDxBRCA is a next generation sequencing based in vitro diagnostic device for qualitative detection of BRCA1 and BRCA2 alterations in formalin- fixed paraffin-embedded (FFPE) ovarian tumor tissue. The FoundationFocus CDxBRCA assay detects sequence alterations in BRCA1 and BRCA2 (BRCA1\/2) genes.","Molecular type":"somatic mutation","Clinical trail ID":"NCT01482715|NCT01891344|NCT02042378","Molecular ID":"BRCA1|BRCA2","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":27},{"Name":"MLH1,PMS2,MSH2,MSH6,BRAF","In a panel":"No","Disease":"colorectal cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Usage":"DiagnosticBM|PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"VENTANA ANTI-MLH-1(M1) MOUSE MONOCLONAL PRIMARY ANTIBODY|VENTANA ANTI-PMS2 (A16-4) MOUSE MONOCLONAL PRIMARY ANTIBODY|VENTANA ANTI-MSH2 (G219-1129) MOUSE MONOCLONAL PRIMARY ANTIBODY|VENTANA ANTI-MSH6 (SP 93) MOUSE MONOCLONAL PRIMARY ANTIBODY|VENTANA ANTI-BRAF V600E (VE1) MOUSE MONOCLONAL PRIMARY ANTIBODY","Test manufacturer":"Ventana Medical Systems","Pmid":"30004261","Treatment":null,"Description":"The VENTANA MMR IHC Panel is indicated in patients diagnosed with colorectal cancer (CRC) to detect mismatch repair (MMR) proteins deficiency as an aid in the identification of probable Lynch syndrome and to detect BRAFV600E protein as an aid to differentiate between sporadic CRC and probable Lynch syndrome.","Molecular type":"multigene prediction","Clinical trail ID":null,"Molecular ID":"MLH1|PMS2|MSH2|MSH6|BRAF","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":28},{"Name":"KRAS,NRAS","In a panel":"No","Disease":"colorectal cancer","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_9256","Usage":"PrognosticBM|PredictiveBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Praxis Extended RAS Panel","Test manufacturer":"Illumina_ Inc.","Pmid":"30019318","Treatment":"Vectibix (panitumumab)","Description":"The PraxisTM Extended RAS Panel is indicated to aid in the identification of patients with colorectal cancer for treatment with Vectibix (panitumumab) based on a no mutation detected test result. The test is intended to be used on the Illumina MiSeqDx instrument.","Molecular type":"somatic mutation","Clinical trail ID":"NCT00364013","Molecular ID":"KRAS|NRAS","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":29},{"Name":"AKT1,ALK,BRAF,CDK4,DDR2,EGFR,ERBB2,ERBB3,FGFR2,FGFR3,HRAS,KIT,KRAS,MAP2K1,MAP2K2,MET,MTOR,NRAS,PDGFRA,PIK3CA,ROS1,RET,SMO","In a panel":"No","Disease":"lung non-small cell carcinoma","Disease ID":"http:\/\/purl.obolibrary.org\/obo\/DOID_3908","Usage":"PrognosticBM","Evidence level":"clinical use","Source":"Tissue","Assay\/Test":"Oncomine Dx Target Test","Test manufacturer":"LIFE TECHNOLOGIES CORPORATION","Pmid":"30243889","Treatment":"-","Description":"The OncomineTM Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high throughput_ parallel-sequencing technology to detect single nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed_ paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGMTM Dx System.","Molecular type":"multigene prediction","Clinical trail ID":null,"Molecular ID":"AKT1|ALK|BRAF|CDK4|DDR2|EGFR|ERBB2|ERBB3|FGFR2|FGFR3|HRAS|KIT|KRAS|MAP2K1|MAP2K2|MET|MTOR|NRAS|PDGFRA|PIK3CA|ROS1|RET|SMO","Type":"Molecular Biomarker","Source ID":"UBERON_0000479","Id":30}]